157 related articles for article (PubMed ID: 38466900)
1. Which Lipid Nanoparticle (LNP) Designs Work? A Simple Kinetic Model Linking LNP Chemical Structure to In Vivo Delivery Performance.
Roh EH; Sullivan MO; Epps TH
ACS Appl Mater Interfaces; 2024 Mar; 16(11):13399-13410. PubMed ID: 38466900
[TBL] [Abstract][Full Text] [Related]
2. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.
Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM
Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715
[TBL] [Abstract][Full Text] [Related]
3. On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA.
Kulkarni JA; Darjuan MM; Mercer JE; Chen S; van der Meel R; Thewalt JL; Tam YYC; Cullis PR
ACS Nano; 2018 May; 12(5):4787-4795. PubMed ID: 29614232
[TBL] [Abstract][Full Text] [Related]
4. Assessing the heterogeneity level in lipid nanoparticles for siRNA delivery: size-based separation, compositional heterogeneity, and impact on bioperformance.
Zhang J; Pei Y; Zhang H; Wang L; Arrington L; Zhang Y; Glass A; Leone AM
Mol Pharm; 2013 Jan; 10(1):397-405. PubMed ID: 23210488
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of macromolecular structure evolution in self-assembled lipid nanoparticles for siRNA delivery.
Gindy ME; DiFelice K; Kumar V; Prud'homme RK; Celano R; Haas RM; Smith JS; Boardman D
Langmuir; 2014 Apr; 30(16):4613-22. PubMed ID: 24684657
[TBL] [Abstract][Full Text] [Related]
6. Determination of the interior pH of lipid nanoparticles using a pH-sensitive fluorescent dye-based DNA probe.
Zhao B; Kamanzi A; Zhang Y; Chan KYT; Robertson M; Leslie S; Cullis PR
Biosens Bioelectron; 2024 May; 251():116065. PubMed ID: 38330772
[TBL] [Abstract][Full Text] [Related]
7. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
8. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.
Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ
Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311
[TBL] [Abstract][Full Text] [Related]
9. The role of lipid components in lipid nanoparticles for vaccines and gene therapy.
Hald Albertsen C; Kulkarni JA; Witzigmann D; Lind M; Petersson K; Simonsen JB
Adv Drug Deliv Rev; 2022 Sep; 188():114416. PubMed ID: 35787388
[TBL] [Abstract][Full Text] [Related]
10. On the role of helper lipids in lipid nanoparticle formulations of siRNA.
Kulkarni JA; Witzigmann D; Leung J; Tam YYC; Cullis PR
Nanoscale; 2019 Nov; 11(45):21733-21739. PubMed ID: 31713568
[TBL] [Abstract][Full Text] [Related]
11. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA.
Chen S; Tam YYC; Lin PJC; Sung MMH; Tam YK; Cullis PR
J Control Release; 2016 Aug; 235():236-244. PubMed ID: 27238441
[TBL] [Abstract][Full Text] [Related]
12. Charge-reversible lipid derivative: A novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery.
Hirai Y; Saeki R; Song F; Koide H; Fukata N; Tomita K; Maeda N; Oku N; Asai T
Int J Pharm; 2020 Jul; 585():119479. PubMed ID: 32473372
[TBL] [Abstract][Full Text] [Related]
13. Investigations into mRNA Lipid Nanoparticles Shelf-Life Stability under Nonfrozen Conditions.
Reinhart AG; Osterwald A; Ringler P; Leiser Y; Lauer ME; Martin RE; Ullmer C; Schumacher F; Korn C; Keller M
Mol Pharm; 2023 Dec; 20(12):6492-6503. PubMed ID: 37975733
[TBL] [Abstract][Full Text] [Related]
14. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.
Basha G; Novobrantseva TI; Rosin N; Tam YY; Hafez IM; Wong MK; Sugo T; Ruda VM; Qin J; Klebanov B; Ciufolini M; Akinc A; Tam YK; Hope MJ; Cullis PR
Mol Ther; 2011 Dec; 19(12):2186-200. PubMed ID: 21971424
[TBL] [Abstract][Full Text] [Related]
15. Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.
Xu Y; Ou M; Keough E; Roberts J; Koeplinger K; Lyman M; Fauty S; Carlini E; Stern M; Zhang R; Yeh S; Mahan E; Wang Y; Slaughter D; Gindy M; Raab C; Thompson C; Hochman J
Mol Pharm; 2014 May; 11(5):1424-34. PubMed ID: 24588618
[TBL] [Abstract][Full Text] [Related]
16. Lipid Nanoparticle (LNP) Chemistry Can Endow Unique
Johnson LT; Zhang D; Zhou K; Lee SM; Liu S; Dilliard SA; Farbiak L; Chatterjee S; Lin YH; Siegwart DJ
Mol Pharm; 2022 Nov; 19(11):3973-3986. PubMed ID: 36154076
[TBL] [Abstract][Full Text] [Related]
17. Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.
Chen S; Tam YY; Lin PJ; Leung AK; Tam YK; Cullis PR
J Control Release; 2014 Dec; 196():106-12. PubMed ID: 25285610
[TBL] [Abstract][Full Text] [Related]
18. Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery.
Alabi CA; Love KT; Sahay G; Yin H; Luly KM; Langer R; Anderson DG
Proc Natl Acad Sci U S A; 2013 Aug; 110(32):12881-6. PubMed ID: 23882076
[TBL] [Abstract][Full Text] [Related]
19. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
[TBL] [Abstract][Full Text] [Related]
20. Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid.
Suzuki Y; Ishihara H
Int J Pharm; 2016 Aug; 510(1):350-8. PubMed ID: 27374199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]